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Abstract
Ampicillin was selected to further study the effect of this antibiotic on the colonization capability
of S. pneumoniae and L. fermentum intranasally inoculated in a mice experimental model. The
sensitivity of S. pneumoniae and L. fermentum to antibiotics was evaluated by different "in vitro"
techniques. The results showed that both microorganisms have a typical pattern of sensitivity to
antibiotics in these assays. The "in vivo" experiments showed that the treatment with Ampicillin
increased the number of lactobacilli and neumococci in the groups of mice treated only with one of
the microorganisms. In those mice treated with Lactobacillus, challenged later with neumococci and
treated with Ampicillin, the pathogen in lung decreased on the 4th day, disappearing completely
after on. The histological studies showed that the antibiotic treatment decreased the inflammatory
response produced by the pathogen at the lung and trachea levels.
Introduction
Respiratory tract infections are commonly caused by Strep-
tococcus pneumoniae. Extensive antibiotic use for these
infections as well as misuse for viral respiratory infections
has led to increased penicillin resistance amongst the
streptococci [1-6]. Even though there is a very broad
description of the pattern of sensibility to antibiotics of
this pathogen and other potentially pathogenic microor-
ganisms, there are a small number of publications referred
to the lactobacilli sensitivity to these types of compounds
[7-10]. The antibiotic treatment modifies the stability of
the normal or indigenous microbiota, producing the
dominance of certain microorganisms able sometimes to
produce a secondary infection [11]. There are a lot of
approaches trying to restore the normal microbiota, or to
avoid modifications of the different ecosystems to prevent
infections, both for human and animal application. One
of the main research areas related to the restoration of the
indigenous flora is the application of probiotic microor-
ganisms [12-14].
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Lactic Acid Bacteria (LAB) has been widely used to restore
the ecologic equilibrium of different areas [12-14], mainly
for the gastrointestinal tract. In the last decade, there is a
lot of other research areas referred to the potential appli-
cation of probiotics in the respiratory tract mainly as vac-
cine vectors [15-17]. They could be applied for the
protection against pathogenic microorganisms as S. pneu-
moniae which is a frequent nasopharynx colonizer. In pre-
vious papers, the isolation and identification of the
microorganisms of the normal microbiota of the respira-
tory tract of mice was reported by our research group.
Also, the evolution from the moment they were born up
to two months age was published [18]. In the isolated
microorganisms, the probiotic or beneficial characteristics
were studied, selecting some strains of the genus Lactoba-
cillus  that shared some properties [19]. From them, a
strain of Lactobacillus fermentum was selected by the bene-
ficial probiotic properties. Later the optimal dose to pro-
duce a transitory colonization or permanence [20,21] and
the protection exerted against S. pneumoniae [22] intrana-
sally inoculated was determined.
The objective of the present paper was to study the effect
of specific antimicrobial agents against the growth of S.
pneumoniae and L. fermentum by "in vitro" assays. Also, to
study the effect of Ampicillin, orally administered in a
mice experimental model, against the intranasal inocula-
tion of S. pneumoniae, L. fermentum or both microorgan-
isms. The "in vivo" assays were complemented with
histological and cytological studies to determine if there
was some type of general response of the animals to the
treatment.
Materials and methods
Microorganisms and culture media
L. fermentum was isolated from the respiratory tract (phar-
ynx) of adult BALB/c mice [18,20-22]. The mutants resist-
ant to Rifampicin (RR) were obtained to differentiate the
inoculated strains from the normal microbiota. The con-
ditions of storage and culture were described previously
[18,20-22]. S. pneumoniae A6 serotype was isolated from
human pneumonia-suffering subjects, and identified by
standard techniques. The serotypification was performed
at the "Servicio de Bacteriología Clínica, Instituto
Nacional de Enfermedades Infecciosas-ANLIS "Dr Carlos
G. Malbran, Buenos Aires, Argentina by Quellung tech-
nique. Pathogenicity in mice was increased by inoculating
S. pneumoniae intraperitoneally [22]. The pathogen was
stored in 25% glycerol added to BHI broth (Brain-Heart
Infusion) at -70°C.
Antibiotics assayed
those antibiotics broadly used for the treatment of Gram
Positive microorganisms affecting the respiratory tract
were studied by determining the Minimal Inhibitory Con-
centration: penicillin, ampicillin, ceftriazone, ceftazidine,
claritromicine, tetracicline, rifampicin, ciprofloxacin,
aztreonam, cloramphenicol and imipenen.
Quantitative determination of the bactericidal activity of 
antibiotics against lactobacilli
The Minimal Inhibitory Concentration Method (MIC)
recommended by the National Committee for Clinical
Laboratory Standards (NCCLS) was used, replacing the
culture media by MRS agar as basal media [23], because
Lactic acid bacteria are not able to grow in the recom-
mended Muller Hinton agar. The reference strains used
were Enterococcus faecalis ATCC 29212 and Staphylococcus
aureus ATCC 29213.
Antibiotic sensitivity of S. pneumoniae. Method of 
diffusion and dilution in agar
The behavior of the pathogenic microorganisms with anti-
microbial substances was determined by the qualitative
and quantitative techniques of diffusion and dilution in
agar (MIC), according to the National Committee for
Clinical Laboratory Standards, 2001 (NCCLS). The antibi-
otics assayed for the qualitative method were oxacillin,
vancomycin, chloramphenicol, tetracycline, rifampicin,
ciprofloxacin, trimetroprim-sulphametoxazol, claritro-
mycin. The antibiotics assayed for the quantitative
method were penicillin, ampicillin, ceftriazone and clari-
tromycin. The reference strain used was S. pneumoniae
ATCC 49619.
"In vivo" assays
Each experimental group (or assay) included 24 to 30 ani-
mals. Four to six mice were killed in each experimental
day. Each one of the "in vivo" experiments was performed
twice, and their data used to calculate the media and
Standard Deviation. The protocols used were accepted by
the Animal Ethics committee of CERELA.
L. fermentum and Ampicillin assay
groups of adult (two months old) male BALB/c mice were
intranasally inoculated with 4 doses of a RR L. fermentum
strain every 12 h. (50 µl of a suspension containing 1 ×
109 CFU/ml). Later, Ampicillin was administered by the
oral way in 4 doses of 100 mg/Kg/day, fractionated in two
daily doses (1.5 mg/dose/mice) every 12 h. The experi-
mental protocol is schematized in Fig 1a.
S. pneumoniae and Ampicillin assay
BALB/c mice were intranasally inoculated with a dose of
50 µl of a suspension of S. pneumoniae in saline solution
(1 × 109 CFU/ml). The antibiotic was administered by the
oral way in 4 doses of 100 mg/Kg/day, following the same
scheme than before. The experimental protocol is schema-
tized in Fig 1b.Annals of Clinical Microbiology and Antimicrobials 2004, 3:23 http://www.ann-clinmicrob.com/content/3/1/23
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Experimental protocols, doses of microorganism and time schedule applied to perform the "in vivo" assays Figure 1
Experimental protocols, doses of microorganism and time schedule applied to perform the "in vivo" assays: Fig 1a: Adminis-
tration of L. fermentum (empty arrows) and Ampicillin (A). Fig 1b: Administration of S. pneumoniae (red arrow) and Ampicillin 
(A). Fig 1c: Administration of L. fermentum, S. pneumoniae and Ampicillin. The days when mice were sacrificed are indicated 
with black crosses.
L.fermentum Antibiotic
1x10
7 CFU  1x10
7   1x10
7   1x10
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12h     12h     12h    12h   12h  12h   12h 
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Fig 1a 
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L. fermentum + S. pneumoniae + Ampicilin assay
Mice were intranasally inoculated with RR L. fermentum (4
doses of 50 µl of a suspension of 1 × 109 CFU/ml), then
challenged with S. pneumoniae A6 by the same way (50 µl
of a suspension of 1 × 109 CFU/ml) and later treated with
Ampicillin in four doses every 12 hours as before, as
shown in Fig 1c.
All the experimental groups were sacrificed by cervical dis-
location on days 2, 4, 7 and 10 post antibiotic administra-
tions. The samples from nasopharynx and pharynx were
obtained with a cotton swab. Trachea, bronchia and lung
were aseptically removed and homogenized with a Teflon
pestle. The number of microorganisms was determined by
the successive dilutions method with peptone water, and
plated in MRS agar-Rifampicin. The plates were incubated
for 24 h. at 37°C in microaerophilic environment. The
identification of microorganisms was performed by mac-
roscopic, microscopic characteristics, Gram staining and
biochemical tests.
Histological studies
the samples for histological assays were obtained from the
higher trachea, located at the neck basis, bronchia in the
area where the main bronchia are divided, and lung in the
terminal bronchiole area and alveolar wall. They were
fixed with 10% paraformaldehyde and stained with
Hematoxylin-eosin and Ramon and Cajal technique [24].
They were analyzed by light microscopy.
Cytological technique
The left lobule of the lung was used to perform the cyto-
logical slices. The organ was first immersed in saline solu-
tion, then fixed in methanol for 3 min, and afterwards
stained with the Romanovsky method (Giemsa stain-
Merck,Germany) used routinely in the lab [25].
Statistical techniques
The numbers in the figures represent the mean and Stand-
ard Deviation of the results obtained in the two set of
experiments performed for each assay. The Student's t test
was applied to determine the differences statistically sig-
nificant of the data.
Results
Antimicrobial sensitivity
L. fermentum
The MIC results for L. fermentum (ug/ml) are as follows:
penicillin, ampicilin, ceftriazone, ceftazidine, rifampicin,
ciprofloxacin:  ≥100 ug/ml, tetraciclin, imipenem and
aztreonam: 10 ug/ml, cloramphenicol 1 ug/ml, claritro-
micine: 0.1 ug/ml. Comparing these values with those
obtained for the MIC of Enterococcus spp and Streptococcus
spp, type strains recommended by NCCLS, L. fermentum
Table 1: Sensitivity of S. pneumoniae to different antimicrobials by the disc diffusion assay
Antibiotic Concentration (ug) Diameter (mm) Results
R(1) S(2)
Oxacillin 1- ≥20 24
Vancomycin 30 - ≥17 22
Chloramphenicol 30 ≤20 ≥21 24
Tetracycline 30 ≤18 ≥23 32
Rifampicin 5 ≤16 ≥19 28
Ciprofloxacin 5 ≤13 ≥17 29
Trimetoprim+Sulphametoxazol 1.25 + 23.75 ≤15 ≥19 26
Claritromicin 15 ≤16 ≥21 25
(1) Resistant, (2) Sensitive.
Table 2: Sensitivity of S. pneumoniae to antimicrobials by the Agar dilution method (MIC)
Antibiotic MIC (ug/ml) Break point Sensitive Results (ug/ml)
Penicillin - ≤0.12 ≤0.02
Ampicillin - ≤0.25 ≤0.10
Ceftriazone ≥2 ≤0.50 ≤0.10
Claritromicin ≥1 ≤0.25 ≤0.02Annals of Clinical Microbiology and Antimicrobials 2004, 3:23 http://www.ann-clinmicrob.com/content/3/1/23
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would be resistant to penicillin, ampicillin, ceftriazone,
rifampicin and ciprofloxacin.
S. pneumoniae
The results of the antimicrobial sensibility of S. pneumo-
niae are shown in Table 1 and 2, demonstrating by the two
methods applied that S. pneumoniae is sensitive to all the
antibiotics assayed by both, the disc diffusion assay, and
the MIC.
"In vivo" assays
from the results obtained in "in vitro" sensitivity assays,
that are predictive, the antibiotic Ampicillin was selected
to be used in "in vivo" assays at the recommended dose for
human beings (equivalent to the one applied to respira-
tory tract infections therapy).
Mice treated with L. fermentum (1 × 107 CFU/ml/dose) and 
Ampicillin
Mice inoculated intranasally with four doses of lactoba-
cilli (determined previously as the dose needed to obtain
colonization of the respiratory tract) and treated with
Colonization of L. fermentum in the respiratory tract of mice obtained after the administration of Ampicillin Figure 2
Colonization of L. fermentum in the respiratory tract of mice obtained after the administration of Ampicillin. The figures 
express the number of L. fermentum in nasal instillations, pharynx, trachea, bronchia or lung from mice inoculated intranasally 
with L. fermentum (4 doses of 107 CFU/mouse) and treated with 4 doses of Ampicillin. The inserted figure shows the number of 
lactobacilli obtained from control mice without antibiotic. (*) indicates differences statistically significant between the two 
groups of mice
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Ampicillin showed an increased colonization of lactoba-
cilli during all the days studied in nasal and pharynx exu-
dates (p < 0.01), with values of 107–8 CFU/organ on days
1 and 4, and lower values on the following days. The
higher number were in nasal and pharynx exudates. In the
control mice without antibiotic, Lactobacillus  numbers
were around 106 CFU on the first days of the assay. On the
7th and 10th days with antibiotic treatment, Lactobacillus
were still present in all the organs, except in lung, while in
the mice without antibiotics they were only present on
nasal and pharynx exudates on day 7 disappearing on day
10 (upper right Figure 2). The results obtained are shown
in Figure 2.
Colonization of S. pneumoniae in the respiratory tract of mice obtained after the administration of Ampicillin Figure 3
Colonization of S. pneumoniae in the respiratory tract of mice obtained after the administration of Ampicillin. The figures 
express the number of S. pneumoniae in nasal instillations, pharynx, trachea, bronchia or lung from mice, challenged with S. 
pneumoniae (108 CFU/mouse) and treated with 4 doses of Ampicillin. The inserted figure shows the number of pathogens 
obtained from control mice without antibiotic. (*) indicates differences statistically significant between the two groups of mice
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Mice challenged with S. pneumoniae (1 × 107 CFU/ml) and treated 
with Ampicillin
Mice challenged with the pathogen and treated with the
antibiotic showed that neumococci were present a longer
time in all the organs of the respiratory tract, (as shown in
Figure 3) compared with the respective mice without anti-
biotic treatment (upper right figure 3). The differences sta-
tistically significant (p < 0.01) between the two groups of
mice are indicated in the figure.
Mice treated with L. fermentum, S. pneumoniae and Ampicillin
The colonization of Lactobacillus in this group was similar
to the one obtained in the experimental group treated
with Lactobacillus and antibiotics without the pathogen
(not showed results) In the case of S. pneumoniae, the pre-
vious treatment with Lactobacillus, reduced significantly
the number of pathogenic microorganism in the lung, as
showed in Fig 4. It was present only on the first day, being
completely cleared on the following days studied.
Histological and cytological studies
The histological studies showed that in all the organs of
the respiratory tract there are not significant structural
modifications. Only a moderate leukocyte exudation is
observed in the alveolar region in the mice treated with S.
pneumoniae and Ampicillin These results are resumed in
Table 3. The administration of Lactobacillus  produces a
stimulation of the lung macrophages, and a lymphocytic
infiltration at the trachea level, as resumed in Table 3 and
Figure 5a. Mice treated with lactobacilli, S. pneumoniae
and antibiotic decreased the inflammatory response pro-
duced by the pathogen (picture 5b) compared with the
pattern produced by the pathogen and antibiotic, repre-
sented in Fig 5c.
The cytological studies showed an increased number of
activated macrophages by Lactobacillus,  neumococci, or
both. The addition of the antibiotic produces an activa-
tion of the non-specific line of defense represented by the
alveolar macrophages, as shown in Table 4.
Discussion
One of the main goals of our research is to go further into
the mechanisms involved in the probiotic effect in the res-
piratory tract [26,27]. Having in mind that we have avail-
able a mice experimental model, our interest was focused
in the knowledge of the effect produced by the antibiotics
more frequently used to treat the respiratory infections on
the kinetics of colonization of both microorganisms,
either separately or combined. We were also interested in
the effect produced by antibiotics on the microbial colo-
nization by the potential use of probiotics together with
antibiotics as therapeutic agents and for the restoration of
the normal microbiota.
Our results showed that the administration of Ampicillin
by the oral route and Lactobacilus intranasally increases
their colonization in the respiratory tract. These results
support the use of antibiotics together with probiotics,
which would help in having a higher colonization of the
protective microorganisms. A paper published by Diele-
men et al [28] demonstrated that the administration of
Lactobacillus GG prevents recurrence of colitis in trans-
genic rats after the treatment with Vancomycin and Imi-
penem, showing that our hypothesis has been proved in
the intestinal tract.
Coincidently with these results, the treatment with Ampi-
cillin, even though the S. pneumoniae strain used was
sensitive to Ampicillin in the "in vitro" test, in the experi-
ments performed in mice produces an increase in the
number of the pathogenic microorganism that are also
present a longer time in the tract. The pathogen produces
a lymphocytic infiltration al the tracheal level, together
with an increased inflammatory response evidenced in
the lung cytological studies.
Why the response to the pathogen is different in "in vitro"
assays than in "in vivo" experiments?. Referred to the
behavior of Lactobacillus, there is a broad discussion based
on the different results obtained through the application
of "in vitro" test, and the differences found in "in vivo"
Colonization S. pneumoniae in mice inoculated intranasally  with L. fermentum (4 doses of 1 × 107 CFU/dose), challenged  with S. pneumoniae (1 × 108 CFU/mice) and treated with 4  doses of Ampicillin compared with mice treated only with  the pathogen and antibiotics Figure 4
Colonization S. pneumoniae in mice inoculated intranasally 
with L. fermentum (4 doses of 1 × 107 CFU/dose), challenged 
with S. pneumoniae (1 × 108 CFU/mice) and treated with 4 
doses of Ampicillin compared with mice treated only with 
the pathogen and antibiotics. The figures express the number 
of pathogen in lung.
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Light microscopy photographs (200×) of histological slices stained with hematoxylin-eosin from mice intranasally treated with  L. fermentum, (5a) S. pneumoniae (5b) or both (5c) and later with Ampicillin Figure 5
Light microscopy photographs (200×) of histological slices stained with hematoxylin-eosin from mice intranasally treated with 
L. fermentum, (5a) S. pneumoniae (5b) or both (5c) and later with Ampicillin. Fig 5a: regular ducts (long arrow) and alveolus 
(short arrow) (100×), Fig 5b: regular mononuclear exudation close to the interalveolar duct (100×). Fig 5c: Increased lym-
phocytic density (100×).Annals of Clinical Microbiology and Antimicrobials 2004, 3:23 http://www.ann-clinmicrob.com/content/3/1/23
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assays. Even though the first one can be used as screening
and to predict some characteristics or properties assayed
in experimental animals models, one must consider that
not always they are coincident [29].
In those experiments performed in mice treated with
Lactobacillus, neumococci and Ampicillin, the final results
is that the pathogen was cleared faster from the lung sup-
porting the combined use of lactobacilli and antibiotics in
the prevention of the infections produced by this patho-
gen. These results are also demonstrated by the
histological slides, (Fig 5c) where the effect produced by
the pneumococci decreased by the concomitant use of
lactobacilli and antibiotics, when compared with the
damage produced by the pathogen administration (Fig
5b). The histological modifications produced by the path-
ogen in mice previously protected with lactobacilli is
lower compared to that obtained when the pathogen
alone is inoculated into mice, [20] which produces
congestion zones and edema in the terminal bronchiolar
area.
The activation of lung or alveolar macrophages produced
by the administration of L. fermentum, S. pneumoniae, or
both, indicates the highly active non-specific branch of
the immune system, which is an important first line of
defense against microbial invasion in the lower airways
infection. This activation could also help in the clearance
of the neumococci observed on the 4th day of the experi-
ments. These results do not agree with those from one
infections produced by Pseudomonas aeruginosa, that does
not produce an activation of the Pulmonary Alveolar Mac-
rophages [30]. The activation of the immune system at the
respiratory tract is taking more relevance, mainly by some
researchers who study this way of administration of differ-
ent antigens and vaccines [15-17].
More studies must be undertaken trying to elucidate
which are the mechanisms involved in the protection
exerted by lactobacilli in the respiratory tract, and also
which are the reasons of the increased colonization of the
pathogen and lactobacilli by the effect of the Ampicillin
treatment.
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